Healthy weight loss
Top tips for healthy weight loss:
To help you find out if you have a healthy body weight, measure your and waist circumference To lose weight, the energy you take in from food must be less than the energy you use – eat less, move more!
Set yourself realistic goals to achieve a healthy weight. Even small amounts of weight loss can have significant health benefits and can help to set you on a path to a healthier future. Guidelines recommend that you should try to lose weight gradually, about 1-2 lbs (approximately 0.5-1.0 kg) a week
Weight loss can reduce your risk of: heart disease, stroke, type 2 diabetes and some cancers.
It can also reduce the risk of:
High blood pressure Angina (heart condition causing chest pain) High blood cholesterol levels Lower back and joint pain Fertility problems BMI and waist circumference
For most adults:
A BMI between 18.5 and 25 is defined as healthy. A BMI of over 25 is defined as overweight. A BMI of over 30 is defined as obese.
Waist-circumferences for which there is an increased risk and high risk of obesity-related health problems:
Increased risk High risk Men ≥94 cm (37 in) ≥102 cm (40 in) Women ≥80 cm (31.5 in) ≥88 cm (34.5 in)
Sensible weight loss should be seen as an overall lifestyle change which involves eating a healthy balanced diet and doing plenty of physical activity.
Guidelines recommend that you should try to lose weight gradually, about 1-2 lbs (approximately 0.5-1.0 kg) a week. This way, the weight is more likely to stay off. This rate of weight loss is based on using up 600 kcal per day more than you take in. On average, this means consuming no more than 1,400 kcal a day if you are a women, and no more than 1,900 kcal a day if you are a man. The amount of weight you lose will depend on how much weight you need to lose and how active you are.
Further information can be found on the manufacturers
Side Effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Orlistat.
The majority of unwanted effects related to the use of Orlistat result from its local action in your digestive system. These symptoms are generally mild, occur at the beginning of treatment and are particularly experienced after meals containing high levels of fat. Normally, these symptoms disappear if you continue treatment and keep to your recommended diet.
Very common (may affect more than 1 in 10 people):
headache abdominal pain/discomfort urgent or increased need to open the bowels flatulence (wind) with or without discharge oily discharge, oily or fatty stools liquid stools low blood sugar levels (experienced by some people with type 2 diabetes) upper respiratory infections flu (influenza)
ErnProduct is a trade name of Gleevec. The active ingredient is isposanyl carbomer 9. Inhaler antibiotics. This medication contains the active ingredient isposanyl carbomer 9. The dosing information for Eumpart is provided in
Most side effects do not require any medical attention and become
so tolerable that the person taking the medicine agrees.
Less common (may affect 1 in 100 people):
headache abdominal pain/discomfort urgent or increased need to open the bowels flatulence (wind) with or without discharge oily discharge, low blood sugar levels (experienced by some people with type 2 diabetes) upper respiratory infections flu (influenza)
Product Reviews
6/13/2025 08:57 Consult your doctor
type of medicine
19alamaco.com review
Consumer friendly
Requires no prescription
Very good at the beginning
At the end of the treatment period (12 weeks), the most common side effects were nausea, vomiting, diarrhoea, headache, and abdominal pain.
Save21%
Original price$ 749.00
Current price$ 595.00
SKU61269-0460-90
Medical Professional License Required to Unlock Account(Note: We don’t Fill Personal Prescriptions)How to Order:
✔Send an email request to: [email protected]
You will receive instructions on how to create an account along with Rx Ordering Details.
Xenical (Orlistat) Capsules 120 mg by H2 Pharma - 90 Count is a premium weight management medication specifically designed to assist individuals in their journey to achieve and maintain a healthier weight. Each capsule contains 120 mg of Orlistat, an active ingredient that helps reduce the absorption of dietary fat by blocking the enzyme that breaks down fat in the digestive system. This promotes weight loss and helps prevent the regaining of lost weight when used in conjunction with a reduced-calorie diet and exercise regimen.
Packaged by H2 Pharma, this product offers 90 easy-to-swallow capsules per bottle, ensuring you have a sufficient supply for an extended period. Xenical is suitable for adults with a body mass index (BMI) of 30 or greater, or for those with a BMI of 27 or greater who have other risk factors such as hypertension, diabetes, or high cholesterol.
With Xenical, not only do you get a clinically proven aid in your weight loss efforts, but you also benefit from a high-quality, reliable product that is crafted with the utmost care and precision. Commit to your weight management goals with Xenical Capsules 120 mg by H2 Pharma and take a step towards a healthier, more fulfilling life.
FAST SHIPPING RISKWe only have 2 custom-made offerings: 90 easy-to-swallow capsules per bottle for 120 mg by H2 Pharma and 80 accurate capsules for 90 easy-to-swallow capsules for 90 easy-to-swallow.
FAST SHIPPING SHAREWe ship all across the world as an independent supplier of Xenical (Orlistat) capsules. Every package is shipped within 7 business days.
In our known market: Xenical (Orlistat) Capsules 120 mg by H2 Pharma is competitively-suited to offer 90 easy-to-swallow capsules per bottle. We are proud to be a reputable pharmacy that guarantees your privacy and confidentiality of your order. Please Note: Our focus is on providing a high-quality service and not on providing a pharmacyied version for your convenience. Our advisory team is best placed to assist you before starting any new medication. We are unable to provide a pharmacyied version of our service that is specifically for your needs. If you need toResidents of Munich, Munich, Germany with a history of mental health or obesity, please inquire about Pharmacyying the residents of Munich, Munich, Germany. If you are considering addressing your obesity issues, please inquire with our health team before starting any new medication. Please note that our service requires a valid prescription from your doctor. If you are unable to obtain a prescription from your healthcare provider, you are required to provide a valid prescription before purchasing this medication.Note: We are unable to provide a pharmacyied version of our medication that is specifically for your needs. Our pharmacyied medication is specifically designed to assist you in losing your weight and maintaining it for you. It is essential to follow the prescribed dosage and schedule that is provided by your healthcare provider. Please inquire with our health team if you are unable to obtain a prescription.
Featured Price: Low to High Price: High to Low Avg. Customer Review Newest ArrivalsSort by
Alli is a top weight-loss brand in Turkey,...View MoreAlli is a top weight-loss brand in Turkey, offering a range of effective products. With trusted reviews and a commitment to quality, Alli helps individuals achieve their weight-loss goals safely and efficiently.View LessRead More
Alli is a brand of medication that is used for weight loss. It contains the active ingredient Orlistat, which blocks the absorption of fat in the body. Alli is sold over-the-counter and is meant to be used in combination with a low-fat, reduced-calorie diet and exercise program.
- Alli was launched in 2007 by GlaxoSmithKline.
- It was the first FDA-approved over-the-counter weight loss medication.
- In 2014, ownership of the brand was transferred to the British company Reckitt Benckiser.
- Alli is currently available in the United States, the United Kingdom, and Australia.
Xenical is a prescription weight loss medication that also contains Orlistat as its active ingredient. It is marketed by Roche Pharmaceuticals and is available in many countries around the world.
PhenQ is a weight loss supplement that contains a blend of natural ingredients. It is marketed by a company called Wolfson Berg Limited and is available for purchase online.
Hydroxycut is a brand of weight loss supplements that are marketed by Iovate Health Sciences International. The brand offers a variety of products that contain different active ingredients, such as caffeine and green coffee extract.
Alli Capsules are the brand's flagship product. Each capsule contains 60mg of Orlistat and is meant to be taken with meals that contain fat.
Alli is used for weight loss. It works by blocking the absorption of fat in the body.
Alli is meant to be taken with meals that contain fat. You should also follow a low-fat, reduced-calorie diet and exercise program while taking this medication.
Alli is generally considered safe when used as directed. However, it can cause some side effects, such as diarrhea and abdominal pain.
Studies have shown that people who take Alli in combination with a diet and exercise program can lose up to 5% of their body weight within six months.
No, Alli is not recommended for use during pregnancy or breastfeeding.
Copyright © 2025 Ubuy Co. All rights reserved.
Asking - As-Sildenafil 100mg - Can I drink alcohol while taking As-Sildenafil 50mg - Can I take As-Sildenafil 50mg - 2019-0022: Like what you see? - 2019-0022 - as-Sildenafil - low effectiveness - This product is not FDA-approved. - as-Sildenafil - low effectiveness - 2020-12-24 - as-Sildenafil - low effectiveness - 2019-12-24 - as-Sildenafil - low effectiveness - 2019-12-24As-Sildenafil (Asildenafil) is a prescription weight loss medication that contains Orlistat as its active ingredient. - As-Sildenafil (Asildenafil) is available in the United States, the United Kingdom, and Australia.AstraZeneca today announced that the company will pay the US Food and Drug Administration for its failure to register an invalid foreign-trade license. The FDA will be required to register the foreign-trade license in a manner that is "so abbreviated" as to include the names of several foreign pharmaceutical companies, including the New Zealand company Ranbaxy.
AstraZeneca is now seeking approval for the registration and marketing of its generic drug, Xenical, as a new drug for the treatment of obesity.
On January 15, 2023, the FDA will issue a final decision in the matter of a new license for the active ingredient of Xenical (the active ingredient in the prescription-only Xenical).
On January 17, 2023, the FDA will issue a final decision in the matter of a new license for the registration and marketing of its generic drug, Xenical, as a new drug for the treatment of obesity.
On January 22, 2023, the FDA will issue a final decision in the matter of a new license for the registration and marketing of its generic drug, Xenical, as a new drug for the treatment of obesity.
On January 25, 2023, the FDA will issue a final decision in the matter of a new license for the registration and marketing of its generic drug, Xenical, as a new drug for the treatment of obesity.
On January 24, 2023, the FDA will issue a final decision in the matter of a new license for the registration and marketing of its generic drug, Xenical, as a new drug for the treatment of obesity.
The FDA will issue a final decision in the matter of a new license for the registration and marketing of its generic drug, Xenical, as a new drug for the treatment of obesity. The FDA will also issue a final decision in the matter of a new license for the registration and marketing of the generic drug, Xenical, as a new drug for the treatment of obesity. The FDA will issue a final decision in the matter of a new license for the registration and marketing of the generic drug, Xenical, as a new drug for the treatment of obesity.
The company will pay the US Food and Drug Administration for the failure to register an invalid foreign-trade license, which will allow it to market Xenical in the US. This is based on an invalid license which will allow the FDA to register the foreign-trade license that is being used to sell Xenical.
The company will pay the US Food and Drug Administration for the failure to register a foreign-trade license in a manner that is "so abbreviated" as to include the names of several foreign pharmaceutical companies, including the New Zealand company Ranbaxy.
The company will pay the US Food and Drug Administration for the failure to register an invalid foreign-trade license in a manner that is "so abbreviated" as to include the names of several foreign pharmaceutical companies, including the New Zealand company Ranbaxy.
On January 18, 2023, the US Food and Drug Administration will issue a final decision in the matter of a new license for the registration and marketing of its generic drug, Xenical, as a new drug for the treatment of obesity.
On January 18, 2023, the FDA will issue a final decision in the matter of a new license for the registration and marketing of its generic drug, Xenical, as a new drug for the treatment of obesity.
Stade de France Pharmacy